Conflict of Interest: Mr. Shah reports no disclosures. Dr. Bendtsen has received honoraria for lectures from Allergan, MSD, and Pfizer, and serves on the scientific advisory board for Berlin-Chemie. Dr. Zeeberg reports no disclosures. Professor R. Jensen has received honoraria for lectures from Allergan, Berlin-Chemie, and MSD, and serves on the scientific advisory board for Allergan and MedoTech.
Reduction of Medication Costs After Detoxification for Medication-Overuse Headache
Article first published online: 20 DEC 2012
© 2012 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 4, pages 665–672, April 2013
How to Cite
Shah, A. M., Bendtsen, L., Zeeberg, P. and Jensen, R. H. (2013), Reduction of Medication Costs After Detoxification for Medication-Overuse Headache. Headache: The Journal of Head and Face Pain, 53: 665–672. doi: 10.1111/head.12031
Financial support: The study was supported by grants from the “IMK Almene Fond.” The founding source was not involved in any stage of the study.
- Issue published online: 4 APR 2013
- Article first published online: 20 DEC 2012
- Accepted manuscript online: 26 NOV 2012 09:21AM EST
- Manuscript Accepted: 19 NOV 2012
- IMK Almene Fond
- medication-overuse headache;
To examine whether detoxifying patients with medication-overuse headache can reduce long-term medication costs.
Direct costs of medications in medication-overuse headache have been reported to be very high but have never been calculated on the basis of exact register data. Long-term economic savings obtained by detoxification have never been investigated.
We conducted a registry-based observational retrospective follow-up study on 336 medication-overuse headache patients treated and discharged from the Danish Headache Center over a 2-year period. By means of the Danish Register of Medicinal Product Statistics, we collected information on the costs and use of prescription-only medication 1 year before admission and 1 year after discharge from Danish Headache Center.
The average medication costs per patient per year decreased with 24%, from US$971 before treatment to US$737 after (P = .001), and the average medication use decreased with 14.4% (P = .02). Savings were most pronounced for patients overusing triptans. In this group, the average medication costs per patient per year decreased with 43% (P < .001), while the average triptan use decreased with 38% (P < .001).
The study demonstrates that detoxification of medication-overuse headache at a tertiary headache center has a long-lasting effect on the medication costs and use, in particular among patients overusing triptans. The results may not be generalizable to all countries and may be sensitive to the costs of triptans.